Phase II registrational trial of onapristone in patients with recurrent or metastatic endometrial cancer.

Trial Profile

Phase II registrational trial of onapristone in patients with recurrent or metastatic endometrial cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 May 2016

At a glance

  • Drugs Onapristone (Primary)
  • Indications Endometrial cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Arno Therapeutics
  • Most Recent Events

    • 16 May 2016 According to Arno Therapeutics media release, company closed this study. But the decision was not based on any safety or lack of efficacy signal and the Company will continue to provide onapristone to all patients currently enrolled in this trial on a compassionate use basis.
    • 16 May 2016 Status changed from recruiting to discontinued, as per Arno Therapeutics media release.
    • 30 Mar 2016 According to an Arno Therapeutics media release, status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top